Pacific Biosciences of California, Inc.
PACBHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeOperating under the Medical Devices umbrella, Pacific Biosciences of California, Inc. is a healthcare company. Pacific Biosciences of California, Inc. With a market capitalization of $419.6M, it sits in small-cap territory. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Market Cap
$419.6M
Beta
2.31
P/E (TTM)
—
P/E (Fwd)
-3.33
EPS (TTM)
$-0.42
EPS (Fwd)
$-0.41
ROE
-929.3%
ROA
-14.1%
Cash
$236.9M
Total Debt
$709.1M
Free CF
$291.6M
52W Change
3.0%
Annual Financials
Cash vs Debt
Where PACB stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, PACB finished 3.31% above its 150-day moving average ($1.51) and 5.45% below its 200-day moving average ($1.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PACB overbought or oversold?
At the August 27, 2026 close, PACB's RSI(14) was 71.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PACB has $236.9M in cash with $709.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $291.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -929.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $128.3M (2022) to $160.0M (2025), reflecting a 25% increase over the period.
With a beta above 1.5, PACB tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Pacific Biosciences of California, Inc.'s trajectory.